TNF and inflammatory bowel disease: Between 10% and 40% of patients with IBD do not respond to the remission induction regimen (known as non-response or failure) and, among primary response patients, up to 30–40% will lose the response during anti-TNF maintenance therapy (secondary non-response or secondary failure) [20,21,25,26].